Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
Back

Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients

Completed

Open to: ALL

Age: 18.0 - N/A

Coventry Bolton Bath Edinburgh Trowbridge Aylesbury Mortimer Reading Addlestone Bury St Edmonds Cookstown Ecclesfield

Medical Conditions

Diabetes Mellitus
Diabetes Mellitus, Type 2

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2008 Dec 2009

Publications

"Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011 Sep;34(9):2015-22. doi: 10.2337/dc11-0606. Epub 2011 Aug 4."; "21816980"; "Nauck M, del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, Parikh SJ. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin]. Dtsch Med Wochenschr. 2013 Apr;138 Suppl 1:S6-15. doi: 10.1055/s-0032-1305283. Epub 2013 Mar 25. German."; "23529570"

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks

Intervention Arm Group : 1;

Intervention Type : DRUG
Intervention Description : Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks

Intervention Arm Group : 2;

Intervention Type : DRUG
Intervention Description : Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks

Intervention Arm Group : 1;2;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Coventry
  • Research Site
    Bolton
  • Research Site
    Bath
  • Research Site
    Edinburgh
  • Research Site
    Trowbridge
  • Research Site
    Aylesbury
  • Research Site
    Mortimer Reading
  • Research Site
    Addlestone
  • Research Site
    Bury St Edmonds
  • Research Site
    Cookstown
  • Research Site
    Ecclesfield


The study is sponsored by AstraZeneca and is in collaboration with Bristol-Myers Squibb.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT00660907
Last updated 10 March 2015

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top